Renal Cancer
News
Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Kidney Cancer
(06/04/2008)
According to updated results from a Phase III clinical trial, initial treatment of metastatic kidney cancer with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).
Urologic and Colorectal Cancer Rates Linked in New Study
(05/22/2008)
Individuals who have been diagnosed with urologic cancers have an increased risk of developing colorectal cancer, and vice versa, according to data recently published in the Archives of Internal Medicine. These results may provide potential changes in screening guidelines.
Updates in the Management of Prostate and Kidney Cancers
(05/07/2008)
A report from the 2008 ASCO Genitourinary Cancers Symposium
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Blood Pressure Monitoring Recommended for Kidney Cancer Patients Treated with Nexavar®
(02/06/2008)
Recent research indicates that patients diagnosed with kidney cancer who are treated with targeted agent Nexavar® (sorafenib) are at an increased risk of developing hypertension (high blood pressure). In order to prevent potential cardiovascular complications, such individuals should have their blood pressure monitored. These results were reported in Lancet Oncology.
More
Renal Cancer
Cancer News...